Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Thoracic Malignancies
•
Medical Oncology
Would a BRAF V600E mutation affect your decision to give adjuvant therapy in a patient with lung cancer?
Related Questions
Would you offer immunotherapy to a patient with stage II NSCLC with an EGFR exon 20 mutation?
Would you give adjuvant sunvozertinib to patients with stage II-III NSCLC with an EGFR exon 20 insertion mutation?
Would you consider omitting concurrent chemoradiation for a patient with stage III EGFR-mutant NSCLC and initiating treatment with osimertinib instead?
How do you approach Tarlatamab use in an elderly patient with relapsed ES SCLC?
Under what circumstances, if any, would you wait on initiating a TKI for metastatic recurrence of a Stage III NSCLC which occurred while on consolidative durvalumab to minimize pneumonitis risk?
Would you consider using Elahere for patients with FOLR1-positive metastatic lung adenocarcinoma?
How would you approach treatment for patients with limited stage small cell lung cancer (SCLC) who, after induction chemotherapy with carboplatin/etoposide, develop a new contralateral lung nodule confirmed as SCLC, while their primary tumor shows a partial response?
For a patient with NSCLC harboring an EGFR or ALK mutation that transforms into SCLC, would you add immunotherapy to chemotherapy or avoid immunotherapy given the tumor's EGFR/ALK origin?
How do you approach a patient with stage IIA non-small cell lung cancer who received SBRT?
How do you determine your next line of therapy In ALK+ metastatic NSCLC patients who have widespread progression on first-line lorlatinib?
